Table 2 treatment and evolution of patients
Patient | Preoperative chemotherapy | Surgery | % Viable tumor cells | Post operative chemotherapy | Relapse | Status |
|---|---|---|---|---|---|---|
1 | no | desarticulation of the hip | NAp | no | NAp | dod |
2 | HD MTX, VCR | amputation | NA | CDDP | NAp | dod |
3 | T10 | desarticulation | 100% | DOX, CDDP, bleo, actinomycin, cyclo | lung | dod |
4 | os 87 | resection-reconstruction | 30% | Ifosfamide, vindesine | local | Lost to follow-up |
5 | HD MTX, DOX | resection-reconstruction | 10% | DOX, HD MTX | no | CR1 |
6 | HELP | tigh's amputation | 3% | HELP | bone | dod |
7 | os 87 | amputation | 60% | os87 | lung | dod |
8 | HELP | Trans-iliac amputation | 8% | HELP | no | CR1 second cancer |
9 | os 94 | resection-prothesis | 80% | VP16, ifosfamide | lung | dod |
10 | os 94 | amputation | >50% | os 94 | local | dod |
11 | os 94 | resection-reconstruction | 15% | os 94 | no | CR1 |
12 | os 94 | resection-prothesis | 0% | os 94 | no | CR1 |
13 | no | costectomy | NAp | os 94 | no | CR1 |
14 | os 05 | resection-prothesis | 8% | os 05 | no | CR1 |
15 | os 05 | NA | NA | NA | NA | Lost to follow-up |